Chris Viehbacher, a German-Canadian businessman who was appointed President and Chief Executive Officer and a member of the Board of Directors of Biogen Inc. (NASDAQ: BIIB) on Nov. 10, 2022, has three children with his wife.
Chris keeps his private life out of the media and as a result, the identities of his children are not known.
Chris, who was born on March 26, 1960, graduated from Queen’s University in Kingston, Ontario, Canada and speaks three languages fluently; French, German and English.
Chris kick-started his career at PriceWaterhouseCoopers and in 1988, he joined GlaxoSmithKline,
He worked at GlaxoSmithKline for 20 years, after which he served as global CEO of Sanofi for six years.
During his tenure as CEO, Sanofi overcame the loss of exclusivity of most of its portfolio and pivoted to new sources of growth such as Dupixent, which resulted from the partnership with Regeneron, and in rare and specialty medicines following the acquisition of Genzyme.
Again, under his leadership, Sanofi strengthened and diversified its R&D pipeline and delivered significant value to shareholders.
His last work prior to his appointment by Biogen was with billionaire Ernesto Bertarelli.
They founded Gurnet Point Capital, a Cambridge-based healthcare investment fund, which led to the creation and continuing development of many innovative companies.
